Background: TRTP‐101 is a novel regenerative therapy consisting of autologous adipose‐derived mesenchymal stem cells (ADMSCs) formed into three‐dimensional (3D) microtissues (microblocks, MiBs). The living 3D MiBs are designed to be extracellular matrix–enriched and organoid/tissue‐like, supporting sustained trophic signaling following intradermal delivery for atrophic scars. Objectives: This study was conducted to assess the safety and tolerability of TRTP‐101 in adults with atrophic scars. Methods: In this first‐in‐human, Phase I, single‐arm pilot study, adults (≥ 19 years) with atrophic scars meeting prespecified criteria underwent autologous adipose harvest from the abdomen and subsequent intradermal administration of TRTP‐101 (1 × 10 7 cells/mL; up to 0.2 mL per scar) into four target scars per participant. Safety was the primary endpoint. Exploratory efficacy was assessed using percentage change in depression volume measured by 3D image analysis at Weeks 1, 4, 8, 12, and 24, with follow‐up extending up to 1 year. Results: Three participants received TRTP‐101 and completed 1‐year follow‐up. No dose‐limiting toxicities, treatment‐related adverse events, or late‐onset reactions were observed throughout the follow‐up period. The mean percentage reductions in atrophic scar volume were 21.27%, 19.72%, 18.88%, and 26.60% at Weeks 1, 4, 8, and 12, respectively, with a mean reduction of 19.31% at 1 year. Conclusions: A single intradermal administration of TRTP‐101 was well tolerated throughout 1 year and showed early, quantifiable reductions in scar depression volume, with a mean reduction still observed at 1 year. This first‐in‐human study may provide preliminary support for the safety and potential regenerative role of autologous ADMSC‐derived 3D MiBs for atrophic scars and supports further controlled clinical evaluation. Trial Registration : ClinicalTrials.gov NCT06210919 (first posted January 18, 2024) and NCT06435884 (first posted May 30, 2024)